Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events or adverse events Death due to methadone use · individuals dependent on illicit opiates
1 finding from 1 review
Serious adverse events or complications of treatment — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (all included trials) ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (all included trials) ICH‐GCP 1997 (low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol leads to higher all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events at 1 year · adults with biliary sphincter of Oddi dysfunction
It is very uncertain whether summary of findings table ‐ Endoscopic sphincterotomy changes proportion of participants with ≥ 1 serious adverse events at 1 year compared with sham treatment (very low certainty).
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events at 1 year · adults with biliary sphincter of Oddi dysfunction
It is very uncertain whether summary of findings table ‐ Endoscopic sphincterotomy changes proportion of participants with ≥ 1 serious adverse events at 1 year compared with endoscopic papillary balloon dilation (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious (penicillin versus cefotaxime) · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious (penicillin versus cefotaxime) compared with other antibiotics (very low certainty).
1 finding from 1 review
Adverse events assessed as: adverse events (serious and non‐serious) · people undergoing peripheral nerve repair of the upper limb
It is very uncertain whether bioengineered devices changes adverse events assessed as: adverse events (serious and non‐serious) compared with standard techniques (very low certainty).
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
It is very uncertain whether heated tobacco use changes serious adverse events – measured by self‐report and medical records compared with cigarette smoking (very low certainty).
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious (penicillin versus doxycycline) · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious (penicillin versus doxycycline) compared with other antibiotics (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · the management of chronic obstructive pulmonary disease
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review